Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Pharma Capital, Ltd. is a private equity firm established by experienced industry executives with a strong background in investment management, drug development, and strategic marketing. Founded in London, UK, the firm also has a significant presence in New York, USA. Pharma Capital focuses on creating value through investments in preclinical and early clinical-stage therapeutics, aiming to advance these assets through proof-of-concept to address high unmet medical needs in the life sciences sector.
The firm operates globally, targeting investments in North America and Europe. Although specific quantitative metrics such as fund size or portfolio count are not disclosed, Pharma Capital is recognized for its unique operational involvement model, which enhances the likelihood of success for its investments. The firm has established itself as a key player in the life sciences investment space, leveraging its deep expertise to navigate the complexities of drug development.
Pharma Capital specializes in direct investments in drug assets, particularly at the preclinical and early clinical stages. The firm employs innovative de-risking strategies and technologies to optimize investments and mitigate development risks. This approach is designed to avoid costly late-stage failures while addressing the demand for innovative products in areas of high unmet medical need, particularly in biotech and healthcare.
The firm operates independently of economic cycles, providing an alternative investment vehicle for global investors. Pharma Capital's investment strategy focuses on high-value therapeutic assets, utilizing a hybrid model that combines private equity financial structures with drug development expertise. This model allows the firm to actively participate in the development of therapeutic assets, enhancing the potential for successful outcomes.
Joseph Grippo - Managing General Partner. Joseph has over 30 years of experience in pharma, biotech, and private equity. He previously served as President and CEO at Pharma Management L.P., a $650 million private equity fund focused on late-stage clinical assets. He co-founded Protodigm Ltd., a UK virtual drug development company, and pioneered accelerated virtual drug development models.
Raphael Santi - Senior Vice President, Portfolio Manager. Raphael brings extensive experience in managing portfolios within the life sciences sector, focusing on maximizing value through strategic investments.
Kevin McGraw - Chief Operating Officer & Head of Underwriting. Kevin oversees the operational aspects of the firm, ensuring that investments align with Pharma Capital's strategic goals.
Katrina Edwards - J.D. Katrina provides legal expertise and guidance on regulatory matters, ensuring compliance throughout the investment process.
To pitch Pharma Capital, founders should send an email to Corporate@pharmacapital.co.uk. The pitch deck should include a comprehensive overview of the therapeutic asset, its development stage, and the unmet medical need it addresses. Founders should also outline their team's qualifications and any preliminary data supporting their claims.
Response times may vary, but founders should expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review of the pitch.
What are Pharma Capital's investment criteria?
Pharma Capital focuses on preclinical and early clinical-stage therapeutics, particularly in the biotech and healthcare sectors. The firm seeks high-value therapeutic assets that address significant unmet medical needs.
How can startups apply or pitch to Pharma Capital?
Startups can pitch to Pharma Capital by sending an email to Corporate@pharmacapital.co.uk. It is advisable to include a detailed overview of the therapeutic asset, its development stage, and the unmet medical need it addresses.
What makes Pharma Capital different from other investors?
Pharma Capital differentiates itself through its unique operational involvement model, which enhances the likelihood of success for its investments by actively participating in the development of therapeutic assets.
What is the geographic scope of Pharma Capital's investments?
The firm invests globally, with a particular focus on North America and Europe, targeting innovative life sciences companies in these regions.
What is the typical check size for investments?
While specific check sizes are not disclosed, Pharma Capital operates within the pre-seed to Series A+ funding stages, indicating a range that typically aligns with early-stage investments in the life sciences sector.
What kind of post-investment involvement does Pharma Capital have?
Pharma Capital is known for its active participation in the development of therapeutic assets, utilizing its expertise to guide companies through key value inflection points.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.